Comparing Apalutamide and Enzalutamide in Real-World Treatment of mCSPC

Benjamin H. Lowentritt, MD, FACS, of Chesapeake Urology, sheds light on a real-world comparison of PSA response in patients with de novo metastatic castration-sensitive prostate cancer treated with apalutamide versus enzalutamide.

Join Today
Abiraterone, Enzalutamide, Darolutamide, and Apalutamide: How Oncologists Decide
▶︎

Abiraterone, Enzalutamide, Darolutamide, and Apalutamide: How Oncologists Decide

Managing an Elevated PSA: Avoiding Unnecessary Prostate Biopsies
▶︎

Managing an Elevated PSA: Avoiding Unnecessary Prostate Biopsies

Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Case-Based Discussion
▶︎

Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Case-Based Discussion

Treatments for #ProstateCancer Bone Metastasis | #MarkScholzMD #AlexScholz #PCRI
▶︎

Treatments for #ProstateCancer Bone Metastasis | #MarkScholzMD #AlexScholz #PCRI

Apalutamide vs Enzalutamide: Insights on Real-World Survival Benefits and Clinical Implications
▶︎

Apalutamide vs Enzalutamide: Insights on Real-World Survival Benefits and Clinical Implications

Active Surveillance for Gleason 7 Prostate Cancer with Minhaj Siddiqui, MD [EP 70]
▶︎

Active Surveillance for Gleason 7 Prostate Cancer with Minhaj Siddiqui, MD [EP 70]

Prostate Biopsy Trap: What Most Men Aren’t Told
▶︎

Prostate Biopsy Trap: What Most Men Aren’t Told

Rationale, Dose Escalation for 67Cu-SAR-bisPSMA in Patients With mCRPC
▶︎

Rationale, Dose Escalation for 67Cu-SAR-bisPSMA in Patients With mCRPC

New FDA Approved PARP Inhibitor: Talzenna (Talazoparib) & Xtandi | #markscholzmd #AlexScholz #pcri
▶︎

New FDA Approved PARP Inhibitor: Talzenna (Talazoparib) & Xtandi | #markscholzmd #AlexScholz #pcri

Metastatic Prostate Cancer
▶︎

Metastatic Prostate Cancer

Enzalutamide Approved for Prostate Cancer With Biochemical Recurrence: Stephen Freedland, MD
▶︎

Enzalutamide Approved for Prostate Cancer With Biochemical Recurrence: Stephen Freedland, MD

PSA Less than 0.01 - Next Steps, Testosterone After Hormone Therapy | Answering YouTube Comments #58
▶︎

PSA Less than 0.01 - Next Steps, Testosterone After Hormone Therapy | Answering YouTube Comments #58

Maximizing Results: 1st & 2nd Generation Hormone Therapy From The Outset? #MarkScholzMD #AlexScholz
▶︎

Maximizing Results: 1st & 2nd Generation Hormone Therapy From The Outset? #MarkScholzMD #AlexScholz

Real-world PSA responses to apalutamide or enzalutamide in mCSPC
▶︎

Real-world PSA responses to apalutamide or enzalutamide in mCSPC

Choosing Systemic Therapy for Men with Metastatic Hormone Sensitive Prostate Cancer
▶︎

Choosing Systemic Therapy for Men with Metastatic Hormone Sensitive Prostate Cancer

STAMPEDE: Does abiraterone (with or without enzalutamide) benefit men with prostate cancer?
▶︎

STAMPEDE: Does abiraterone (with or without enzalutamide) benefit men with prostate cancer?

16 Years: Surviving Metastatic #ProstateCancer | Joel Nowak, CEO of @Cancer ABCs | #PCRI
▶︎

16 Years: Surviving Metastatic #ProstateCancer | Joel Nowak, CEO of @Cancer ABCs | #PCRI

Updated overall survival outcomes in ENZAMET (ANZUP 1304)
▶︎

Updated overall survival outcomes in ENZAMET (ANZUP 1304)

Combining Hormone Therapies for #ProstateCancer | #MarkScholzMD #AlexScholz #PCRI
▶︎

Combining Hormone Therapies for #ProstateCancer | #MarkScholzMD #AlexScholz #PCRI

Prostate Biopsy: Should I have it done?
▶︎

Prostate Biopsy: Should I have it done?